Carl Zeiss Meditec AG wins patent infringement action on trifocal intraocular lens against VSY Biotechnology and Fritz Ruck Ophthalmologische Systeme GmbH
Carl Zeiss Meditec AG has won a patent infringement action before the District Court of Düsseldorf/Germany against VSY Biotechnology BV and its exclusive distribution partner Fritz Ruck Ophthalmologische Systeme GmbH. The District Court recently ruled that the trifocal intraocular lens offered by these companies infringes the European patent EP 2377493 B1 of Carl Zeiss Meditec AG.
JENA/Germany, 27/03/2017.
The patent protects a special aphakic intraocular lens (IOL), with which light can be focused on three focal points (near, intermediate and distance vision). The patented trifocal lens reduces the impact of pupil shrinkage and lens eccentricity.
VSY Biotechnology BV and its exclusive distribution partner Fritz Ruck Ophthalmologische Systeme GmbH were convicted by the court to recall all their trifocal lenses on the market and destroy all such lenses in their possession.
Intraocular lenses are used primarily to treat cataracts. In recent years, the development of innovative new lenses has considerably enhanced treatment options. Trifocal intraocular lenses such as the ZEISS AT LISA® tri and the AT LISA® tri toric which are highly esteemed by physicians, enable patients to see well at all distances – often without them needing eyeglasses.
Contact for investors and press:
Sebastian Frericks
Director Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220-116
investors .meditec @zeiss .com
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases, including implants and consumable materials. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 2,900 employees worldwide, the Group generated revenue of € 1,088 million in financial year 2015/16 (to 30 September).
The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading companies in the optical and optoelectronic industries.
For more information visit our website at:
www.zeiss.com/med
